AstraZeneca PLC
26 October 2000
ASTRAZENECA TO OUTSOURCE GLOBAL IT INFRASTRUCTURE
SERVICES TO IBM
AstraZeneca today announced that it has identified IBM as
its preferred supplier of global Information Technology
(IT) infrastructure services. This is subject to
signature of a contract, the key terms of which have
already been established in principle with IBM. A
further announcement will be made once a contract has
been signed.
Some 1200 people worldwide (AstraZeneca employees and
contract staff) are currently engaged in the provision of
IT infrastructure services to AstraZeneca. All 'in-
scope' AstraZeneca employees will be offered employment
by IBM and detailed consultations are commencing with
employees and their representatives.
Jon Symonds, Chief Financial Officer of AstraZeneca,
said, 'This partnership will enable AZ to sharpen the
focus of its Information Services (IS) capabilities on to
the strategic opportunities such as e-business and
informatics in R&D, and further encourage added value
from IS activities. Once finalised, the partnership will
give AZ enhanced technical power and provide better
opportunities for personal development for these IT
professionals, as well as significant cost savings.'
Frank Kern, General Manager, Professional Services, IBM
Global Services, said, 'We are extremely pleased to have
been selected by AstraZeneca as the preferred supplier to
outsource their IT infrastructure on a global basis.
AstraZeneca is a leading pharmaceutical company, with
extensive research capabilities, operating around the globe.
We recognise the critical importance of a robust IT
infrastructure to support their business, and how
this partnership can help AstraZeneca focus on strategic
IS opportunities.'
- 2 -
ABOUT ASTRAZENECA
AZ is a major international healthcare business engaged
in the research, development, manufacture and marketing
of ethical (prescription) pharmaceuticals and the supply
of healthcare services. It is one of the top five
pharmaceutical companies in the world with healthcare
sales of over $15 billion and leading positions in sales
of gastrointestinal, oncology, anaesthesia including pain
management, cardiovascular, central nervous system (CNS)
and respiratory products.
ABOUT IBM
IBM is the world's largest information technology
company, with 80 years of leadership in helping businesses
innovate. IBM offers a wide range of services, solutions
and technologies that enable companies to take full
advantage of the new era of e-business. IBM Global
Services is the world's largest information technology
services provider, with 1999 revenues of more than $32 billion.
Services is the fastest growing part of IBM, with more
than 138,000 professionals serving customers in 160 countries.
IBM Global Services integrates IBM's broad range of
capabilities - services, hardware, software and research -
to help companies of all sizes realise the full value of
information technology. For more information on IBM, visit
www.ibm.com.
October 26, 2000
For further information:
Michael Olsson: Tel. +44 (0)20 7304 5087
Ed Seage: Tel +44 (0)20 7304 5100
Jorgen Winroth: Tel. +1 609 896 4148
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.